We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Need immediate shipping of stoppers or seals? West has an efficient niche operation for small quantity fulfillment: our facility in Lititz, Pennsylvania. For those seeking samples, small quantity fulfillment for research and development needs or just a few components, Lititz offers off the shelf, convenient, fast and friendly customer service.
The Lititz facility is home to specialty repackaging and distribution, including distribution of the West Ready Pack®system, which features a combination of ready-to-use vials, stoppers and seals in small quantities. In fact, Lititz is capable of providing same-day turnaround on small quantity fulfillment.
The facility also focuses on assembly – a production operation that requires obtaining various components from a variety of sources, maintaining the appropriate levels of stock and assembling and repackaging in controlled conditions – as well as customization to suit the needs of customers.
So if you need just a few components, contact your account manager to learn how the staff at our Lititz facility is by your side.
West Ready Pack® is a registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
As of 2018, over 4,000 new injectable drug products are in development world wide – a great many of these in small settings such as universities, medical research institutes, and small companies. These efforts need the ready availability of high quality, sterile packaging products in small volumes for developmental and clinical phases.
Biologics is a rapidly growing market, with a robust R&D pipeline bringing innovative therapies to treat patients. Today, there are 4,000 more active biologic programs in the pipeline compared to 2015, with biologics development programs growing 2.5 times faster than small molecules. New entrants into the biologics market are driving this rapid growth. As of 2018, emerging companies represented 84% of all early phase research.<sup>1</sup> Not only is this segment driving R&D growth, but they are having commercial success in bringing their drugs to market. In 2018, 65% of new drugs launched were patented by emerging companies.<sup>1</sup>
There is no doubt biologics and biosimilars will remain one of the hot topics in 2021. This is due to the pandemic period of SARS-CoV-2 and the innovative treatments and vaccines that are under development at accelerated speed. Several questions can arise regarding selection of the proper primary package system for a biologic/biosimilar.
Gene therapies are developed by modifying a person’s genes and are often targeted to treat complex and chronic diseases. Due to advancements in science and research, gene therapy is positioned to transform treatment options for patients who are living with these incurable diseases. There is a growing pipeline of gene therapies globally, with 352 global trials underway at the end of 2019, up 12% from 2017.<sup>1.</sup>
The definitions of <em>personalized medicine</em> vary. However, all of them indicate that the once popular therapy approach of “<em>one drug fits all</em>” is outdated. The Council of the European Union defines personalized medicine as <em>“[p]roviding the right treatment to the right patient, at the right dose at the right time.”</em><sup>[1]</sup>.
English
Chinese
